Author name: Claritas Rx

In the rapidly evolving world of healthcare, cell and gene therapies stand out as groundbreaking advancements that hold the potential to radically change patient outcomes. For pharma manufacturers and patient services teams, navigating these complex therapies requires unprecedented strategies and innovations. This blog delves into the intricacies of the patient journey, the role of patient […]

In a groundbreaking move that is set to revolutionize the pharmaceutical industry, Formation Bio, Sanofi, and OpenAI have joined forces to introduce Muse, an AI tool poised to transform patient recruitment in drug development. This collaboration unites the expertise of three industry giants, each bringing unique strengths to the table, all aimed at accelerating the

Tackling the intricacies of rare disease treatments demands comprehensive patient support programs. These initiatives are vital for individuals who encounter unique obstacles when accessing treatments and managing their conditions. To ensure these programs’ effectiveness, it is crucial to assess their impact accurately, which is where Key Performance Indicators (KPIs) become essential. This guide delves into

In the intricate world of cancer treatment, AvenCell Therapeutics has made waves with its recent achievement. The company successfully raised $112 million in a Series B funding round to further develop its promising CAR-T cell therapies targeting acute myeloid leukemia (AML). This funding is a significant stride toward tackling what many in the industry call “the

The biopharmaceutical industry stands on the brink of a technological revolution. Artificial Intelligence (AI) is poised to transform how drugs are discovered, developed, and delivered. This transformation is not just a future vision; it’s happening now, with significant developments emerging almost weekly. In this blog post, we’ll take a deep dive into the recent advancements

Navigating the complex world of pharmaceutical distribution can be daunting for market access teams and pharmaceutical professionals. At the heart of this complexity lies the buy-and-bill model, a predominant method for distributing provider-administered drugs. This blog post aims to clarify how the buy-and-bill model works, explore its benefits and challenges, and provide insights into emerging

The Federal Reserve’s recent decision to cut interest rates has sent ripples through various industries, but what does it mean for biopharma? Last week, the Fed announced a rate cut by half a percentage point, marking the first reduction since March 2020. This move has been met with a mixture of optimism and caution within

Emerging from stealth mode with a bang, Vironexis Biotherapeutics has announced a successful $26 million seed funding round. This is not just another startup story; it’s a significant development in the realm of cancer gene therapy. For pharmaceutical professionals and biopharma executives, understanding Vironexis’ vision and innovations could provide crucial insights into the future of